Yuan Cheng

Dr. Yuan Cheng

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
CWChendong Wang
Chendong Wang
BLBin Leng
Bin Leng
RYRan You
Ran You
ZYZeyu Yu
Zeyu Yu
YLYa Lu
Ya Lu
QXQingyu Xu
Qingyu Xu
Purpose: The response to transarterial chemoembolization (TACE) varies among individuals with hepatocellular carcinoma (HCC). This study aimed to identify a biomarker for predicting TACE response in HCC patients and to investigate its correlations with the tumor microenvironment and pre-TACE radiomics features. Patients and Methods: GSE104580 data were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed gene analysis and machine learning algorithms were used to identify genes for constructing the TACE failure signature (TFS). TFS scores were then calculated for HCC patients in The Cancer Genome Atlas (TCGA) cohort. After obtaining images from The Cancer Imaging Archive (TCIA), tumor labeling and radiomics feature extraction, the Rad-score model was generated. Correlation analysis was performed between the TFS score and the Rad-score. CIBERSORT, ssGSEA and TME analysis were performed to explore differences in the immune landscape among distinct risk groups. The immunotherapy response was compared between different groups. Results: ADH1C, CXCL11, EMCN, SPARCL1 and LIN28B were selected and incorporated into the TFS, which demonstrated satisfactory performance in predicting TACE response. Patients in the high TFS score group had poorer overall survival (OS) than those in the low TFS score group. The Rad-score model was constructed using six radiomics features, and the Rad-score was significantly correlated with hub gene expression and the TFS score. The high-TFS group was also characterized by an immunosuppressive tumor microenvironment and exhibited unfavorable responses to immunotherapy with PD-1 and CTLA-4 checkpoint inhibitors. Conclusion: This study established a transcriptomic biomarker for predicting the efficacy of TACE that correlates with radiomics features on pretreatment imaging, tumor immune microenvironment characteristics, and the efficacy of immunotherapy and targeted therapy in HCC patients.

19 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
RYRan You
Ran You
YCYuan Cheng
Yuan Cheng
LDLingfeng Diao
Lingfeng Diao
CWChendong Wang
Chendong Wang
BLBin Leng
Bin Leng
GYGuowen Yin
Guowen Yin
Purpose: In the present study, we aimed to assess the effectiveness and safety of immune-targeted therapy (IT) with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Patients and methods: This was a multicenter retrospective study that included 265 HCC patients with PVTT (IT + TACE: 82, IT: 183). Overall survival (OS) and progression-free survival (PFS), as well as tumor responses and adverse events, were evaluated. Results: Patients in the IT + TACE group experienced significantly longer overall survival (OS) and progression-free survival (PFS) periods, compared with those in the IT group (OS 19.0 vs. 13.0 months, p < 0.001; PFS 12.0 vs. 7.3 months, p < 0.001). Multivariable analysis confirmed IT + TACE as an independent predictor for improved OS and PFS. Subgroup analysis demonstrated the benefits of IT + TACE in patients with rich PVTT blood supply. Preoperative imaging and DSA offered predictive value. Conclusions: TACE combined with IT provides a safe and effective treatment option for advanced-HCC patients with PVTT, particularly those with abundant PVTT blood supply.

1 February 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
XZXiao-Dong Zhu
Xiao-Dong Zhu
LZLei Zhao
Lei Zhao
BLBinkui Li
Binkui Li
YCYuan Cheng
Yuan Cheng
HSHui-Chuan Sun
Hui-Chuan Sun
In recent years, the standard treatment for hepatocellular carcinoma (HCC) has changed dramatically due to the emergence of potent systemic treatment options. These advanced therapies have led to increased survival benefits for patients with advanced or intermediate-stage HCC. Advancements in HCC treatments also offer the possibility of conversion therapy for initially unresectable HCC. However, the treatment of HCC is becoming increasingly complex, due to the expanding availability of systemic therapies, their use in combination with locoregional therapies, and their perioperative applications. Patient characteristics such as liver function, esophageal and gastric variceal status, and treatment goal (downstaging resection or long-term maintenance treatment), are the most critical factors when selecting a systemic treatment strategy. Consequently, the necessity to tailor a personalized and comprehensive treatment strategy for individual patients is growing. This review briefly summarizes the current systemic treatment regimens for HCC from a surgeon’s perspective. It is based on results from clinical studies as well as personal experience and introduces the concept of a patient-centered, treatment goals-driven, individualized systemic treatment strategy for managing HCC.

1 October 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
XSXiao Shen
Xiao Shen
JZJin-Xing Zhang
Jin-Xing Zhang
JLJin Liu
Jin Liu
SLSheng Liu
Sheng Liu
HSHai-Bin Shi
Hai-Bin Shi
QZQing-Quan Zu
Qing-Quan Zu
Purpose: Transarterial chemoembolization (TACE), when used in combination with immunotherapy and antiangiogenic therapy, has been shown to have synergistic anticancer effects. The aim of this study was to further assess the efficacy and safety of TACE combined with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC) in the real world. Methods: Between August 2021 and September 2023, clinical information was collected from consecutive HCC patients who received treatment via TACE-Atezo/Bev at four tertiary institutions. This study evaluated the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) as outcomes. Predictors for OS and PFS were also analyzed. Treatment-related adverse events (TRAEs) were recorded and assessed. Results: Ninety-two patients were enrolled in this study, with a median follow-up duration of 14.1 months. The ORRs based on the modified Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria were 54.3% and 41.3%, respectively. The median OS and PFS of the patients were 15.9 months [95% confidence interval (CI), 14.5– 17.2 months] and 9.1 months (95% CI, 7.4– 10.8 months), respectively. Multivariate analyses revealed that the Eastern Cooperative Oncology Group score and neutrophil‒lymphocyte ratio were independent risk factors for OS, whereas tumor size and extrahepatic metastasis were independent risk factors for PFS. Grade 3/4 TRAEs occurred in 16.3% (15/92) of the patients and were controlled conservatively. Conclusion: The combination of Atezo/Bev with TACE demonstrated acceptable synergistic therapeutic effects and manageable safety profiles in patients with unresectable HCC.

1 June 2026 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
YCYuan Cheng
Yuan Cheng
KXKunlin Xie
Kunlin Xie
Immune checkpoint inhibitor–based combination therapies have increased the likelihood that a subset of patients with initially unresectable hepatocellular carcinoma (HCC) may achieve sufficient tumor regression to become technically resectable However, when resectability emerges systemic therapy, the optimal next step remains uncertain. Surgical resection may eradicate residual macroscopic disease, whereas continued systemic therapy may help maintain control of occult micrometastatic disease. In this review, we summarize the available evidence on surgical consolidation after conversion and propose a conceptual response-guided consolidation framework to support post-conversion decision-making. The current evidence base remains dominated by retrospective comparative studies, although early randomized data have recently emerged in selected populations. Overall, surgical consolidation appears feasible and may improve progression-related outcomes in carefully selected responders, but definitive survival benefit across all response categories remains unproven. Within the proposed framework, partial response appears to represent the most consistent clinical scenario supporting surgery, stable disease should be interpreted as a heterogeneous category requiring further biological and radiographic discrimination, and complete response remains the most uncertain setting in which surgery may not always be necessary. Beyond radiographic response alone, pathological response and biomarker-based predictive enrichment may help refine future selection strategies. We therefore suggest that post-conversion resectability should be viewed not simply as a technical surgical endpoint, but as a therapeutic decision point requiring multidisciplinary assessment of anatomical feasibility, response depth and durability, hepatic reserve, and biological risk. This proposed framework is intended as a practical interim model rather than an established clinical standard and requires prospective validation.

30 July 2025 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
YCYuan Cheng
Yuan Cheng
YZYaodong Zhang
Yaodong Zhang
CLChangxian Li
Changxian Li
XLXiangcheng Li
Xiangcheng Li
Introduction: Cholangiocarcinoma (CCA) carries a high risk of recurrence even after curative resection. Capecitabine is standard adjuvant therapy, but recurrence rates remain significant, particularly in high-risk patients. Immunotherapy has shown promise in advanced CCA, prompting investigation into its role in earlier settings. Methods and analysis: This multicentre, randomised, open-label phase II trial will compare adjuvant adebrelimab plus capecitabine versus capecitabine alone in patients with high-risk resected CCA. The study is being conducted at four tertiary hospitals in Jiangsu Province, China. Eligible patients will be randomised 1:1. The primary endpoint is 1-year recurrence-free survival rate (1y-RFS rate). Secondary endpoints are overall survival, RFS and safety. Exploratory endpoints are circulating tumour DNA (ctDNA)-based MRD assessment. Ethics and dissemination: The study is approved by the Institutional Review Board of Jiangsu Provincial People’s Hospital (2024-SR571). Informed consent will be obtained from all participants. The findings will be published in peer-reviewed journals and presented at scientific conferences. Trial registration number: NCT06607276 .